172896-85-4

Upstream product

• 172896-35-4 ethyl N-methyl-N-phenylthiocarbamoylacetate 
• 108-20-3 di-isopropyl ether 
• 124-38-9 carbon dioxide 
• 5310-07-6 N-methyl-N-phenylthioacetamide 
• 100-61-8 N-methylaniline 

Downstream Products

• 172896-66-1 ethyl 2-{methyl-[2-(methyl-phenyl-thiocarbamoyl)-acetyl]-amino}-5-pyrrol-1-yl-benzoate 
• 5310-07-6 N-methyl-N-phenylthioacetamide 
• 485810-83-1 ethyl 2-{methyl-[2-(methyl-phenyl-thiocarbamoyl)-acetyl]-amino}-5-(methylthio)-benzoate 

Relevant academic research and scientific papers

DRUGS AUGMENTING NKT CELLS

There is provided a NKT cell augmentation-mediated autoimmunosuppressant and/or potentiator on normal immune responses characterized by its comprising a compound of the following general formula or a pharmaceutically acceptable salt thereof as an active ingredient.[wherein R1 represents hydrogen or halogen,R2 represents hydroxy,R3 represents lower alkyl,R4 represents lower alkyl,R5 represents hydrogen or lower alkoxy, andZ represents O or S] Also provided is a novel process for synthesizing the above compound.

The first synthesis of N-alkyl-N-arylthiocarbamoylacetates and acetic acids

N-Alkyl-N-arylthiocarbamoylacetates, the key intermediates for the synthesis of novel antinephritic agents, have been prepared for the first time. Some of the esters were in turn hydrolyzed to the corresponding acids. An alternative, indirect synthetic route was also developed to prepare some unusual acids.